ES2345882T3 - Nuevos compuestos y su uso como moduladores de ppar. - Google Patents
Nuevos compuestos y su uso como moduladores de ppar. Download PDFInfo
- Publication number
- ES2345882T3 ES2345882T3 ES03757741T ES03757741T ES2345882T3 ES 2345882 T3 ES2345882 T3 ES 2345882T3 ES 03757741 T ES03757741 T ES 03757741T ES 03757741 T ES03757741 T ES 03757741T ES 2345882 T3 ES2345882 T3 ES 2345882T3
- Authority
- ES
- Spain
- Prior art keywords
- compounds
- new compounds
- ppar modulators
- compositions
- ppar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title abstract 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108010015181 PPAR delta Proteins 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
- C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
- C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/708—Ethers
- C07C69/712—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/42—Singly bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Semiconductor Memories (AREA)
- Optical Integrated Circuits (AREA)
Abstract
Un compuesto de la fórmula general (I): **(Ver fórmula)** en la que X1 es arilo o heteroarilo, cada uno de los cuales está opcionalmente sustituido con uno o más sustituyentes seleccionados de - halógeno, hidroxi, ciano, amino o carboxi; o - alquilo C1-6, cicloalquilo C3-6, alquenilo C2-6, alquinilo C2-6, aralquilo, heteroaralquilo, alcoxi C1-6, cicloalcoxi C3-6, ariloxi, aralcoxi, heteroaralcoxi, alquil C1-6 tio, ariltio, cicloalquil C3-6 tio, alquil C1-6 carbonilo, arilcarbonilo, alquil C1-6 sulfonilo, alquil C1-6 sulfoniloxi, arilsulfonilo, arilsulfoniloxi, alquil C1-6 amido, arilamido, alquil C1-6 aminocarbonilo, alquil C1-6 amino, dialquil C1-6 amino o cicloalquil C3-6 amino, cada uno de los cuales está opcionalmente sustituido con uno o más halógenos; y X2 es arilo o heteroarilo, cada uno de los cuales está opcionalmente sustituido con uno o más sustituyentes seleccionados de - halógeno, hidroxi, ciano, amino o carboxi; o - alquilo C1-6, cicloalquilo C3-6, alquenilo C2-6, alquinilo C2-6, aralquilo, heteroaralquilo, alcoxi C1-6, cicloalcoxi C3-6, ariloxi, aralcoxi, heteroaralcoxi, alquil C1-6 tio, ariltio, cicloalquil C3-6 tio, alquil C1-6 carbonilo, arilcarbonilo, alquil C1-6 sulfonilo, alquil C1-6 sulfoniloxi, arilsulfonilo, arilsulfoniloxi, alquil C1-6 amido, arilamido, alquil C1-6 aminocarbonilo, alquil C1-6 amino, dialquil C1-6 amino o cicloalquil C3-6 amino, cada uno de los cuales está opcionalmente sustituido con uno o más halógenos; y Ar es arileno que está opcionalmente sustituido con uno o más sustituyentes seleccionados de - halógeno, hidroxi o ciano; o - alquilo C1-6, cicloalquilo C3-6, alquenilo C2-6, alquinilo C2-6, arilo, heteroarilo, aralquilo, heteroaralquilo, alcoxi C1-6, cicloalcoxi C3-6, ariloxi, aralcoxi, heteroaralcoxi, alquil C1-6 tio, ariltio o cicloalquil C3-6 tio, cada uno de los cuales está opcionalmente sustituido con uno o más halógenos; y Y1 es O o S; y Y2 es O o S; y Z es -(CH2)n- en el que n es 1, 2 ó 3; y R1 es hidrógeno, halógeno o un sustituyente seleccionado de - alquilo C1-6, cicloalquilo C3-6, alquenilo C2-6, alquinilo C2-6, aralquilo, heteroaralquilo, alcoxi C1-6, cicloalcoxi C3-6, ariloxi, aralcoxi, heteroaralcoxi, alquil C1-6 tio, ariltio o cicloalquil C3-6 tio, cada uno de los cuales está opcionalmente sustituido con uno o más halógenos; y R2 es hidrógeno, alquilo C1-6, cicloalquilo C3-6, alquenilo C2-6, alquinilo C2-6, alqueninilo C4-6 o arilo; o una de sus sales farmacéuticamente aceptables, o uno de sus solvatos farmacéuticamente aceptables, o cualquier forma tautomérica, estereoisómeros, mezcla de estereoisómeros, incluida una mezcla racémica o polimorfos.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200201631 | 2002-10-28 | ||
| DK200201631 | 2002-10-28 | ||
| DK200300793 | 2003-05-26 | ||
| DKPA200300793 | 2003-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2345882T3 true ES2345882T3 (es) | 2010-10-05 |
Family
ID=32178576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03757741T Expired - Lifetime ES2345882T3 (es) | 2002-10-28 | 2003-10-27 | Nuevos compuestos y su uso como moduladores de ppar. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1558572B1 (es) |
| JP (1) | JP4708184B2 (es) |
| KR (1) | KR20050061562A (es) |
| AT (1) | ATE472526T1 (es) |
| AU (2) | AU2003273783C1 (es) |
| BR (1) | BR0315683A (es) |
| CA (1) | CA2503280A1 (es) |
| DE (1) | DE60333211D1 (es) |
| ES (1) | ES2345882T3 (es) |
| MX (1) | MXPA05004402A (es) |
| NO (1) | NO20052575L (es) |
| PL (1) | PL376718A1 (es) |
| RU (1) | RU2349582C2 (es) |
| WO (1) | WO2004037776A2 (es) |
| ZA (1) | ZA200502814B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7129268B2 (en) * | 2002-10-28 | 2006-10-31 | Novo Nordisk A/S | Peroxisome proliferator activated receptor-active arylene acetic acid derivatives |
| EP2100877B1 (en) | 2003-09-19 | 2012-01-25 | Janssen Pharmaceutica N.V. | 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| MXPA06003019A (es) * | 2003-10-28 | 2006-06-23 | Reddys Lab Ltd Dr | Nuevos compuestos y su uso en medicina: proceso para su preparacion y composiciones farmaceuticas que los contienen. |
| EP1745014B1 (en) | 2004-05-05 | 2011-07-06 | High Point Pharmaceuticals, LLC | Novel compounds, their preparation and use |
| MXPA06013195A (es) * | 2004-05-14 | 2007-02-14 | Irm Llc | Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar). |
| JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| EA201101084A1 (ru) | 2005-12-22 | 2012-04-30 | ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Феноксиуксусные кислоты в качестве активаторов ppar дельта |
| UY30288A1 (es) | 2006-04-18 | 2007-08-31 | Janssen Pharmaceutica Nv | Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol |
| WO2007141295A1 (en) * | 2006-06-08 | 2007-12-13 | High Point Pharmaceuticals, Llc | Process for preparing phenoxy acetic acid derivatives |
| ES2811087T3 (es) | 2013-09-09 | 2021-03-10 | Vtv Therapeutics Llc | Uso de agonistas de PPAR-delta para tratar la atrofia muscular |
| WO2021099966A2 (en) * | 2019-11-19 | 2021-05-27 | Nibn, The National Institute For Biotechnology In The Negev Ltd. | Novel benzothiophene derivatives and use thereof for stimulating mitochondrial turnover |
| CA3185909A1 (en) | 2020-07-22 | 2022-01-27 | Reneo Pharmaceuticals, Inc. | Crystalline ppar-delta agonist |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1011651B1 (en) | 1996-02-02 | 2005-04-27 | Merck & Co., Inc. | Method of treating diabetes and related disease states |
| ATE236137T1 (de) | 1996-02-02 | 2003-04-15 | Merck & Co Inc | Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit |
| DE69723680T9 (de) | 1996-02-02 | 2004-11-04 | Merck & Co., Inc. | Antidiabetische mittel |
| ES2217392T3 (es) | 1996-02-02 | 2004-11-01 | MERCK & CO., INC. | Agentes antidiabeticos. |
| AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| US5773469A (en) | 1996-06-18 | 1998-06-30 | Ortho Pharmaceutical Corporation | Diaryl antimicrobial agents |
| ES2258799T3 (es) | 1996-12-23 | 2006-09-01 | MERCK & CO., INC. | Agentes antidiabeticos. |
| ES2320181T3 (es) | 1997-07-24 | 2009-05-19 | Astellas Pharma Inc. | Composiciones farmaceuticas que tienen un efecto reductor del colesterol. |
| AU3958000A (en) * | 1999-04-20 | 2000-11-02 | Novo Nordisk A/S | New compounds, their preparation and use |
| GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| JP2001354671A (ja) | 2000-04-14 | 2001-12-25 | Nippon Chemiphar Co Ltd | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
| EP1310494B1 (en) | 2000-08-11 | 2012-01-25 | Nippon Chemiphar Co., Ltd. | PPAR (delta) ACTIVATORS |
| GB0031103D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| CZ2004133A3 (cs) * | 2001-07-30 | 2004-06-16 | Novo Nordisk A/S | Deriváty vinylkarboxylové kyseliny, farmaceutický prostředek ho obsahující a jeho použití |
-
2003
- 2003-10-27 MX MXPA05004402A patent/MXPA05004402A/es active IP Right Grant
- 2003-10-27 RU RU2005116243/04A patent/RU2349582C2/ru not_active IP Right Cessation
- 2003-10-27 BR BR0315683-4A patent/BR0315683A/pt not_active IP Right Cessation
- 2003-10-27 JP JP2005501509A patent/JP4708184B2/ja not_active Expired - Fee Related
- 2003-10-27 KR KR1020057007096A patent/KR20050061562A/ko not_active Withdrawn
- 2003-10-27 ES ES03757741T patent/ES2345882T3/es not_active Expired - Lifetime
- 2003-10-27 DE DE60333211T patent/DE60333211D1/de not_active Expired - Lifetime
- 2003-10-27 PL PL376718A patent/PL376718A1/pl not_active Application Discontinuation
- 2003-10-27 EP EP03757741A patent/EP1558572B1/en not_active Expired - Lifetime
- 2003-10-27 CA CA002503280A patent/CA2503280A1/en not_active Abandoned
- 2003-10-27 AT AT03757741T patent/ATE472526T1/de not_active IP Right Cessation
- 2003-10-27 AU AU2003273783A patent/AU2003273783C1/en not_active Ceased
- 2003-10-27 WO PCT/DK2003/000722 patent/WO2004037776A2/en not_active Ceased
-
2005
- 2005-04-07 ZA ZA2005/02814A patent/ZA200502814B/en unknown
- 2005-05-27 NO NO20052575A patent/NO20052575L/no not_active Application Discontinuation
-
2010
- 2010-04-19 AU AU2010201560A patent/AU2010201560A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003273783A1 (en) | 2004-05-13 |
| WO2004037776A2 (en) | 2004-05-06 |
| MXPA05004402A (es) | 2005-07-26 |
| AU2010201560A1 (en) | 2010-05-06 |
| CA2503280A1 (en) | 2004-05-06 |
| KR20050061562A (ko) | 2005-06-22 |
| EP1558572A2 (en) | 2005-08-03 |
| RU2349582C2 (ru) | 2009-03-20 |
| WO2004037776A3 (en) | 2004-06-10 |
| JP4708184B2 (ja) | 2011-06-22 |
| ZA200502814B (en) | 2005-12-28 |
| BR0315683A (pt) | 2005-08-30 |
| AU2003273783B2 (en) | 2010-03-18 |
| JP2006503908A (ja) | 2006-02-02 |
| AU2003273783C1 (en) | 2010-08-12 |
| PL376718A1 (pl) | 2006-01-09 |
| EP1558572B1 (en) | 2010-06-30 |
| RU2005116243A (ru) | 2006-01-20 |
| ATE472526T1 (de) | 2010-07-15 |
| NO20052575L (no) | 2005-05-27 |
| DE60333211D1 (de) | 2010-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007005205A (es) | Compuestos biciclicos sulfonilo-sustituidos como moduladores de receptores activados por el proliferador de la peroxisoma. | |
| MXPA04000891A (es) | Nuevos derivados de acido vinilcarboxilico y su uso como antidiabeticos. | |
| SG10201809390QA (en) | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | |
| DE602007008524D1 (de) | Spiroimidazol-derivate als ppar-modulatoren | |
| CL2009000323A1 (es) | Compuestos derivados de heterociclos no condensados sustituidos, inhibidores de la funcion de la proteina ns5a; composicion farmaceutica que los comprende; y su uso para tratar la infeccion del virus de la hepatitis c. | |
| CL2009000324A1 (es) | Compuestos derivados de heterociclos no condensados sustituidos, inhibidores de la funcion de la proteina ns5a; composicion farmaceutica que los comprende; y su uso para tratar la infeccion del virus de la hepatitis c. | |
| CY1111050T1 (el) | Φωσφονικα, μονοφωσφοναμιδικα, διφωσφοναμιδικα για την αγωγη των ιϊκων παθησεων | |
| WO2007089557A3 (en) | Polycyclic 1, 2, 3, 4 -tetrahydro- isoquinoline derivatives and compositions comprising them as ppar modulators | |
| WO2007101864A3 (en) | Compounds that modulate ppar activity, their preparation and use | |
| CL2004000778A1 (es) | Compuestos derivados de heterociclos de 5 miembros, inhibidores de la porteina tirosina fosfatasa 1b (ptp1b); composiciones farmaceuticas, utiles para tratar hipertension, obesidad, diabetes, hiperlipidemia. | |
| MX2007011023A (es) | 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3. | |
| DK1392282T3 (da) | Dermatologiske og kosmetiske sammensætninger, der omfatter et furfurylderivat | |
| EA201101084A1 (ru) | Феноксиуксусные кислоты в качестве активаторов ppar дельта | |
| EA200700489A1 (ru) | Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств | |
| CL2008002689A1 (es) | Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia. | |
| CL2009000119A1 (es) | Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer. | |
| CY1106973T1 (el) | Παραγωγα θειαζολινης ως εκλεκτικοι διαμορφωται υποδοχεως ανδρογονου (sarms) | |
| BRPI0417858A (pt) | composto, composição farmacêutica, e, uso de uma composição farmacêutica | |
| ATE472526T1 (de) | Neue verbindungen und deren verwendung als ppar- modulatoren | |
| CO5660287A2 (es) | Derivados de tetrahidrocarbazol y su uso farmaceutico | |
| PL376704A1 (pl) | Nowe związki przydatne w leczeniu chorób, w których pośredniczy PPAR | |
| CL2008003182A1 (es) | Compuestos derivados de 1,2,4-triazol-3-amino; composicion farmaceutica; y su uso en el tratamiento del dolor, reflujo gastroesofagico, ansiedad, sindrome del intestino irritable. | |
| WO2007056366A3 (en) | Compounds and compositions as ppar modulators | |
| ATE515494T1 (de) | Neue verbindungen, deren herstellung und verwendung | |
| WO2003090672A3 (en) | 2-(quinolonyl)-fused heterocycles as androgen receptor modulators |